Blogs

Notes from BIO 2009: Irish Pharma--Can Innovation and Quality Trump Cost and Infrastructure Considerations?

When Transparency Becomes a Blunt Instrument

Lilly CEO Lechleiter Criticizes Obama's Plans to Close Corporate Tax Loopholes

The Film Behind the Film: The Making of Pfizer's Rat Commercial

FDA's Most Wanted (or, the Rogues Gallery of Biotech)

FDA Cites "Shadow" Heparin Manufacturing Plants in China

Will Chemical Engineers Save Pharma?